PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature

Evgeni Efimenko, Utpal P. Dave, Irina V. Lebedeva, Yao Shen, Maria J. Sanchez-Quintero, Daniel Diolaiti, Andrew Kung, Brian J. Lannutti, Jianchung Chen, Ronald Realubit, Zoya Niatsetskaya, Vadim Ten, Charles Karan, Xi Chen, Andrea Califano, Thomas G. Diacovo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110g and p110d play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aber-rantly upregulated, we now demonstrate that the combined activities of PI3Kg/d have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3Kg/d or a g-secretase inhibitor reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3Kg/d activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3Kg/d inhibition in the context of NOTCH1 and cMYC signaling.

Original languageEnglish (US)
Pages (from-to)2069-2082
Number of pages14
JournalMolecular Cancer Therapeutics
Volume16
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Phosphatidylinositol 3-Kinases
Null Lymphocytes
Amyloid Precursor Protein Secretases
Animal Diseases
Critical Pathways
Tumor Burden
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Energy Metabolism
Genes
Protein Isoforms
Down-Regulation
T-Lymphocytes
Cell Line
Growth
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efimenko, E., Dave, U. P., Lebedeva, I. V., Shen, Y., Sanchez-Quintero, M. J., Diolaiti, D., ... Diacovo, T. G. (2017). PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature. Molecular Cancer Therapeutics, 16(10), 2069-2082. https://doi.org/10.1158/1535-7163.MCT-17-0141

PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature. / Efimenko, Evgeni; Dave, Utpal P.; Lebedeva, Irina V.; Shen, Yao; Sanchez-Quintero, Maria J.; Diolaiti, Daniel; Kung, Andrew; Lannutti, Brian J.; Chen, Jianchung; Realubit, Ronald; Niatsetskaya, Zoya; Ten, Vadim; Karan, Charles; Chen, Xi; Califano, Andrea; Diacovo, Thomas G.

In: Molecular Cancer Therapeutics, Vol. 16, No. 10, 01.10.2017, p. 2069-2082.

Research output: Contribution to journalArticle

Efimenko, E, Dave, UP, Lebedeva, IV, Shen, Y, Sanchez-Quintero, MJ, Diolaiti, D, Kung, A, Lannutti, BJ, Chen, J, Realubit, R, Niatsetskaya, Z, Ten, V, Karan, C, Chen, X, Califano, A & Diacovo, TG 2017, 'PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature', Molecular Cancer Therapeutics, vol. 16, no. 10, pp. 2069-2082. https://doi.org/10.1158/1535-7163.MCT-17-0141
Efimenko, Evgeni ; Dave, Utpal P. ; Lebedeva, Irina V. ; Shen, Yao ; Sanchez-Quintero, Maria J. ; Diolaiti, Daniel ; Kung, Andrew ; Lannutti, Brian J. ; Chen, Jianchung ; Realubit, Ronald ; Niatsetskaya, Zoya ; Ten, Vadim ; Karan, Charles ; Chen, Xi ; Califano, Andrea ; Diacovo, Thomas G. / PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 10. pp. 2069-2082.
@article{00704cb717054119876898a6fc8309f9,
title = "PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature",
abstract = "PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110g and p110d play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aber-rantly upregulated, we now demonstrate that the combined activities of PI3Kg/d have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3Kg/d or a g-secretase inhibitor reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3Kg/d activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3Kg/d inhibition in the context of NOTCH1 and cMYC signaling.",
author = "Evgeni Efimenko and Dave, {Utpal P.} and Lebedeva, {Irina V.} and Yao Shen and Sanchez-Quintero, {Maria J.} and Daniel Diolaiti and Andrew Kung and Lannutti, {Brian J.} and Jianchung Chen and Ronald Realubit and Zoya Niatsetskaya and Vadim Ten and Charles Karan and Xi Chen and Andrea Califano and Diacovo, {Thomas G.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0141",
language = "English (US)",
volume = "16",
pages = "2069--2082",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - PI3Kg/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature

AU - Efimenko, Evgeni

AU - Dave, Utpal P.

AU - Lebedeva, Irina V.

AU - Shen, Yao

AU - Sanchez-Quintero, Maria J.

AU - Diolaiti, Daniel

AU - Kung, Andrew

AU - Lannutti, Brian J.

AU - Chen, Jianchung

AU - Realubit, Ronald

AU - Niatsetskaya, Zoya

AU - Ten, Vadim

AU - Karan, Charles

AU - Chen, Xi

AU - Califano, Andrea

AU - Diacovo, Thomas G.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110g and p110d play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aber-rantly upregulated, we now demonstrate that the combined activities of PI3Kg/d have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3Kg/d or a g-secretase inhibitor reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3Kg/d activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3Kg/d inhibition in the context of NOTCH1 and cMYC signaling.

AB - PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110g and p110d play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aber-rantly upregulated, we now demonstrate that the combined activities of PI3Kg/d have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3Kg/d or a g-secretase inhibitor reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3Kg/d activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3Kg/d inhibition in the context of NOTCH1 and cMYC signaling.

UR - http://www.scopus.com/inward/record.url?scp=85030623404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030623404&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0141

DO - 10.1158/1535-7163.MCT-17-0141

M3 - Article

C2 - 28716817

AN - SCOPUS:85030623404

VL - 16

SP - 2069

EP - 2082

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -